NCT01755429已完成不适用
A Research Study to Describe the Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS). An Assessment of Two Case Studies
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2
- 试验地点
- 2
- 主要终点
- Change in platelet count from baseline
研究概览
简要总结
This protocol is intended to formally collect data on the treatment of aHUS with eculizumab in Japanese patients.
研究设计
- 研究类型
- Observational
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient and/or legal guardian must be willing and able to give written informed consent and id the patient is not an adult and able to read and write, the patient is willing to give written informed assent
- •Eculizumab treatment initiated as personal importation for aHUS in 201
排除标准
- •Not Applicable
结局指标
主要结局
Change in platelet count from baseline
时间窗: 26 weeks
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)Atypical Hemolytic Uremic Syndrome (aHUS)NCT01757431Alexion Pharmaceuticals, Inc.2
已完成
不适用
A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)Atypical Hemolytic Uremic Syndrome (aHUS)NCT01770951Alexion Pharmaceuticals, Inc.30
已完成
1 期
A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaLeukemia, Lymphocytic, Chronic, B-CellNCT00923182Genzyme, a Sanofi Company6
已完成
2 期
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)Atypical Hemolytic Uremic SyndromeNCT00838513Alexion Pharmaceuticals, Inc.15
已完成
3 期
Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and PharmacokineticsPain, IntractableNCT00216684Janssen Pharmaceutical K.K.139